Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background —The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with coronary heart disease (CHD) and serum cholesterol 5.5 to 8.0 mmol/L (213 to 310 mg/dL) with triglycerides ≤2.5 mmol/L (220 mg/dL) to simvastatin 20 to 40 mg or placebo once daily. Over the median follow-up period of 5.4 years, one or more major coronary events (MCEs) occurred in 622 (28%) of the 2223 patients in the placebo group and 431 (19%) of the 2221 patients in the simvastatin group (34% risk reduction, P <.00001). Simvastatin produced substantial changes in several lipoprotein components, which we have attempted to relate to the beneficial effects observed. Methods and Results —The Cox proportional hazards model was used to assess the relationship between lipid values (baseline, year 1, and percent change from baseline at year 1) and MCEs. The reduction in MCEs within the simvastatin group was highly correlated with on-treatment levels and changes from baseline in total and LDL cholesterol, apolipoprotein B, and less so with HDL cholesterol, but there was no clear relationship with triglycerides. We estimate that each additional 1% reduction in LDL cholesterol reduces MCE risk by 1.7% (95% CI, 1.0% to 2.4%; P <.00001). Conclusions —These analyses suggest that the beneficial effect of simvastatin in individual patients in 4S was determined mainly by the magnitude of the change in LDL cholesterol, and they are consistent with current guidelines that emphasize aggressive reduction of this lipid in CHD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Law, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210
Cited by
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
“001 Diabetes Yes No 116/318 (36) 214/949 (23) 88/309 (28) 170/955 (18) 24 (¡0.”
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationWood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
Walldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,229
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Prepared by: British Cardiac Society, B. H. S. (2005) · Heart · doi:10.1136/hrt.2005.079988 · Cited by 1,216
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Clinical Practice Recommendations
Fowler, M. J. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.4.163 · Cited by 995
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention
Munoz (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6269 · Cited by 760
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 707
Douketis, J. D., Macie, C., Thabane, L., & Williamson, D. F. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802982 · Cited by 665
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Self-citationThe evolving role of statins in the management of atherosclerosis
Vaughan, C. J., Gotto, A. M., & Basson, C. T. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00525-2 · Cited by 574
Gotto, A. M., Whitney, E., Stein, E. A., Shapiro, D. R., Clearfield, M., Weis, S., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 563
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature
Messina, M. (2016) · Nutrients · doi:10.3390/nu8120754 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 529
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 498
BARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. C., CHAPMAN, M. J., COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 464
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Sniderman, A., Furberg, C., Keech, A., van Lennep, J. R., Frohlich, J., Jungner, I., & Walldius, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12663-3 · Cited by 457
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Lipoproteins, nutrition, and heart disease
Schaefer, E. J. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.2.191 · Cited by 438
Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density
Wasnich, R. D. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.231 · Cited by 417
Ballantyne, C. M., Olsson, A. G., Cook, T. J., Mercuri, M. F., Pedersen, T. R., & Kjekshus, J. (2001) · Circulation · doi:10.1161/hc5001.100624 · Cited by 416
Self-citationWalldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 396
Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., et al. (2000) · Circulation · doi:10.1161/01.cir.102.16.1893 · Cited by 388
Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes
Lu, W., Resnick, H. E., Jablonski, K. A., Jones, K. L., Jain, A. K., Howard, W. J., Robbins, D. C., & Howard, B. V. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.16 · Cited by 370
Akosah, K. O., Schaper, A., Cogbill, C., & Schoenfeld, P. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00187-6 · Cited by 351
Kaesemeyer, W. H., Caldwell, R. B., Huang, J., & Caldwell, R. W. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00514-2 · Cited by 343
Sniderman, A. D., Scantlebury, T., & Cianflone, K. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00014 · Cited by 336
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 331
Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118356 · Cited by 326
“…Benn et al. 2007 (60 ) Tertile 3 vs 1 M, 1.4 (1.1–1.8); W, 1.5 (1.1–2.1) " less predictive " Age, TC, LDL-C, HDL-C, TG, BMI, hypertension, diabetes, smoking Mora et al. 2007 (71 ) Age, treatment group, smoking, menopausal hormone use, BP, BMI, diabetes Pedersen et al. 1998 (61 ) –10 mg/dL Ϫ5.”
InfluentialWadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
Current overview of statin-induced myopathy
Rosenson, R. S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.033 · Cited by 287
Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Wilt, T. J., Bloomfield, H. E., MacDonald, R., Nelson, D., Rutks, I., Ho, M., Larsen, G., McCall, A., Pineros, S., & Sales, A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1427 · Cited by 275
De Backer, G., Ambrosioni, E., Broch-Johnsen, K., Brotons, C., Cifkova, R., Dallongeville, J., Ebrahim, S., Faergeman, O., Graham, I., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention and Rehabilitation · doi:10.1097/00149831-200312001-00001 · Cited by 274
Pedersen, T. R., Wilhelmsen, L., Færgeman, O., Strandberg, T. E., Thorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T. J., Haghfelt, T., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00910-3 · Cited by 274
Self-citationBarter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p002816 · Cited by 259
Simes, R. J., Marschner, I. C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R. A. H., Hague, W., Keech, A., Thompson, P., White, H., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 254
Kelley, G. A., Kelley, K. S., & Tran, Z. V. (2004) · Journal of Women's Health · doi:10.1089/jwh.2004.13.1148 · Cited by 225
Kokkinos, P. F., Faselis, C., Myers, J., Panagiotakos, D., & Doumas, M. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61426-3 · Cited by 217
Statin myopathy: A common dilemma not reflected in clinical trials
Fernandez, G., Spatz, E. S., Jablecki, C., & Phillips, P. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10073 · Cited by 216
Statin Therapy in the Prevention of Recurrent Cardiovascular Events: A Sex-Based Meta-analysis
Gutierrez, J., Ramirez, G., Rundek, T., & Sacco, R. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.2145 · Cited by 185
Kelley, G. A., & Kelley, K. S. (2007) · Public Health · doi:10.1016/j.puhe.2007.02.014 · Cited by 184
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816100-00003 · Cited by 182
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively
Hunninghake, D. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00437-3 · Cited by 176
Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met
Yan, A. T., Yan, R. T., Tan, M., Hackam, D. G., Leblanc, K. L., Kertland, H., Tsang, J. L., Jaffer, S., Kates, M. L., Leiter, L. A., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.015 · Cited by 158
Ramjee, V., Sperling, L. S., & Jacobson, T. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.009 · Cited by 157
Thanassoulis, G., Williams, K., Ye, K., Brook, R., Couture, P., Lawler, P. R., de Graaf, J., Furberg, C. D., & Sniderman, A. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000759 · Cited by 148
Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137
Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trials
Kelley, G. A., & Kelley, K. S. (2006) · The Journal of Men's Health & Gender · doi:10.1016/j.jmhg.2005.09.003 · Cited by 127
Packard, C. J., Ford, I., Robertson, M., Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L. E. M., Buckley, B. M., Cobbe, S. M., Gaw, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.526848 · Cited by 121
Apolipoproteins as markers and managers of coronary risk
Chan, D. C. (2006) · QJM · doi:10.1093/qjmed/hcl027 · Cited by 117
Soffer, D. E., Marston, N. A., Maki, K. C., Jacobson, T. A., Bittner, V. A., Peña, J. M., Thanassoulis, G., Martin, S. S., Kirkpatrick, C. F., Virani, S. S., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.08.013 · Cited by 115
Evidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
Rader, D. J., Davidson, M. H., Caplan, R. J., & Pears, J. S. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00005-5 · Cited by 84
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.
de Graaf, J., Couture, P., & Sniderman, A. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0982 · Cited by 80
Wang, N., Woodward, M., Huffman, M. D., & Rodgers, A. (2022) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008552 · Cited by 80
Statins induce differentiation and cell death in neurons and astroglia
März, P., Otten, U., & Miserez, A. R. (2007) · Glia · doi:10.1002/glia.20422 · Cited by 75
Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering
Pedersen, T. R. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/1158822-s0-000000000-00000 · Cited by 74
Self-citationLow density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis
Genser, B., & März, W. (2006) · Clinical Research in Cardiology · doi:10.1007/s00392-006-0403-x · Cited by 68
Wood, G., Taylor, E., Ng, V., Murrell, A., Patil, A., van der Touw, T., Sigal, R., Wolden, M., & Smart, N. (2022) · British Journal of Sports Medicine · doi:10.1136/bjsports-2021-103999 · Cited by 45
Plans-Rubió, P. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/11539150-000000000-00000 · Cited by 31
Apolipoprotein A-V gene therapy for disease prevention/treatment: a critical analysis
Trudy, M., Vineeta, S., & Robert, O. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150059 · Cited by 18
Metadata
- Authors
- Pedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., Miettinen, T., Christophersen, B., Tobert, J. A., Musliner, T. A., & Cook, T. J.
- Venue
- Circulation
- Published
- 1998-04-21
- Volume
- 97
- Issue
- 15
- Pages
- 1453-1460
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2011277263
- Cited by
- 621
- References
- 27
- FWCI
- 67.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.